Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04855721
Other study ID # AUR101-202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 4, 2021
Est. completion date December 10, 2022

Study information

Verified date December 2022
Source Aurigene Discovery Technologies Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)


Description:

This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate the efficacy and safety of AUR101 in patients with moderate-to-severe psoriasis. Approximately 128 patients with chronic moderate-to-severe plaque psoriasis (defined as Psoriasis Area and Severity Index (PASI) ≥12 and Body Surface Area (BSA) involved ≥10%) will be randomized to four groups (three dose groups of AUR101 and one placebo group) in the ratio of 1:1:1:1. The patients in each arm will receive AUR101 of 200 mg twice daily, 400 mg twice daily, 400 mg once daily or matching placebo for 16 weeks in a double blind, double dummy fashion. All patients will be followed up for 14 ± 2 days of their last dose for safety assessment.


Recruitment information / eligibility

Status Completed
Enrollment 141
Est. completion date December 10, 2022
Est. primary completion date November 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Confirmed diagnosis of chronic plaque-type psoriasis, diagnosed at least 6 months before screening 2. Psoriasis of at least moderate severity, defined as PASI=12 and involved BSA=10 % at screening and Day 1 3. Static 5-point IGA modified [mod] 2011 scale of 3 or higher at screening and Day 1 4. Adult males or females, = 18 to = 70 years of age 5. Ability to communicate well with the investigator and to comply with the requirements of the entire study 6. Willingness to give written informed consent (prior to any study related procedures being performed) and ability to adhere to the study restrictions and assessments schedule Exclusion Criteria: 1. History of erythrodermic, guttate or pustular psoriasis within last 12 months 2. BMI < 18 or > 40 3. History of lack of response to ustekinumab, secukinumab or ixekizumab (or any therapeutic agent targeted to IL12, IL-17 or IL-23) at approved doses after at least 3 months of therapy 4. Current treatment or history of treatment for psoriasis with any investigational or approved IL-17, IL-12 or IL-23 antagonist biological agents (e.g. secukinumab, briakinumab, tildrakizumab, ustekinumab etc.) within 6 months prior to the first administration of study drug. 5. Current treatment or history of treatment for psoriasis with other investigational or approved biological agents (e.g. anti-TNFa inhibitors - adalimumab, etanercept, infliximab, alefacept etc.) within 3 months prior to the first administration of study drug 6. Current treatment or history of treatment for psoriasis with non-biological systemic medications or immunomodulators (including systemic steroids, apremilast, methotrexate, cyclosporine, acitretin, etc.) or phototherapy within 4 weeks prior to the first administration of study drug. 7. Treatment with medicated topical agents (having active pharmaceutical ingredient that can impact or interfere with the effect of the study drug) within 2 weeks prior to the first administration of study drug. 8. Evidence of organ dysfunction (e.g. liver dysfunction = 1.5 X of ULN for ALT, AST or ALP or Total Bilirubin, or renal dysfunction of = 1.5X of ULN of serum creatinine) 9. Any surgery requiring general anesthesia within 3 months prior to screening 10. History of malignancy within last 5 years except patients with non-melanoma skin cancer or carcinoma in situ of cervix who can participate in the study. Adequately treated cutaneous basal or squamous cell carcinoma are allowed. 11. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV Ab) at screening 12. Patient with known history of systemic tuberculosis or currently suspected or known to have active tuberculosis 13. Patient expected to be started on anti-tubercular therapy either for treatment or prophylaxis of tuberculosis 14. Suspected tuberculosis infection as evident from a positive QuantiFERON TB-Gold test (QFT) or Mantoux test (MT) at screening. Patients with a positive QFT or MT may participate in the study if further work up as per the opinion of the investigator (like Chest X-ray or CT scan of Chest or other locally acceptable method for diagnosing active tuberculosis) establishes that patient does not have active tuberculosis. Patients with latent tuberculosis should not be enrolled except when they are not planned to start prophylaxis for tuberculosis during the study period. 15. History of hypersensitivity or idiosyncratic reaction to any investigational ROR-gamma inhibitors or any of the excipients of study drug 16. History of alcohol or substance abuse that will affect compliance to study procedures/schedule as per Investigator opinion 17. Any previous gastrointestinal surgery or recent (within 3 months) / current history of gastrointestinal disease, that in the opinion of investigator, could impact the absorption of the study drug 18. Positive pregnancy test for women of child-bearing potential (WOCBP) at the screening or randomization visit 19. Male patients who are sexually active with WOCBP, not willing to use reliable contraception methods as mentioned in section 8.14 20. Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable contraceptive methods (hormonal contraceptive, IUD or any double combination of male or female condom, spermicidal gel, diaphragm, sponge, cervical cap). Please see section 8.14 for acceptable contraceptive practices 21. Has received any investigational biologic agents within 3 months or 5 half-lives (whichever is longer) prior to the first administration of study drug 22. Has received another new chemical entity/non-biologic investigational drug within 28 days or 5 half-lives of investigational drug (whichever is longer) prior to study day 1 23. History of other auto-immune disorders (except psoriasis and psoriatic arthritis) where treatment with systemic immunosuppressants is required 24. History of active infection and/or febrile illness within 7 days prior to Day 1. The infection adequately treated by antibiotics during the screening period as per investigator opinion will be allowed to undergo randomization, provided patient is stable for at least 7 days before randomization 25. Current swab-positive or suspected (under investigation) Covid-19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of person(s) with confirmed Covid-19 infection, at screening or Day 1 26. History or presence of any major medical illness (e.g. renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, or local active infection/infectious illness) or psychiatric disease, or clinically significant laboratory / ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study 27. History of any unstable cardiac (including Class III or IV congestive heart failure by New York Heart Association Criteria), respiratory, hepatic, renal or other systemic conditions within 3 months prior to first study drug administration 28. Use of herbal remedies, mega dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of study drug 29. Patients who have received live attenuated vaccine in the 4 weeks prior to the first administration of study drug -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AUR101
Oral ROR-gamma inverse agonist
Placebo
Placebo

Locations

Country Name City State
United States Great Lakes Research Group, Inc Bay City Michigan
United States Moore Clinical Research, Inc. Brandon Florida
United States Skin Research Institute Coral Gables Florida
United States Dermatology Treatment & Research Center Dallas Texas
United States Accel Research Sites - Deland CRU DeLand Florida
United States FXM Clinical Research Fort Lauderdale Fort Lauderdale Florida
United States Johnson Dermatology Fort Smith Arkansas
United States First OC Dermatology Fountain Valley California
United States Abys New Generation Research Inc. Hialeah Florida
United States Direct Helpers Research Center Hialeah Florida
United States Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana
United States Dermatology Research Associates Los Angeles California
United States Floridian Reserach Miami Florida
United States FXM Clinical Research Miami LLC Miami Florida
United States FXM Clinical Research Miramar LLC Miramar Florida
United States Sadick Research Group New York New York
United States The Dermatology Specialists New York New York
United States Paddington Testing Co, Inc Philadelphia Pennsylvania
United States Northwest AR Clinical Trials Center Rogers Arkansas
United States Medisearch Clinical Trials Saint Joseph Missouri
United States University Clinical Trials, Inc. San Diego California
United States Clinical Science Institute Santa Monica California
United States Unison Clinical Trials Sherman Oaks California
United States Lenus Research & Medical Group, LLC Sweetwater Florida
United States Center for Clinical Studies Ltd., LLP. Webster Texas

Sponsors (1)

Lead Sponsor Collaborator
Aurigene Discovery Technologies Limited

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Metabolite of AUR101 identification from plasma collected at week 4 AUR101 metabolites identification in plasma (currently the metabolites are unidentified and no more details are available) Week 4
Other Metabolite of AUR101 quantification from plasma collected at week 4 AUR101 metabolites quantification in plasma AUR101 (currently the metabolites are unidentified and no more details are available) Week 4
Other Metabolite of AUR101 identification from urine collected at week 4 AUR101 metabolites identification in urine (currently the metabolites are unidentified and no more details are available) Week 4
Other Metabolite of AUR101 quantification from urine collected at week 4 AUR101 metabolites quantification in urine (currently the metabolites are unidentified and no more details are available) Week 4
Other Proportion of patients achieving PASI 75 response PASI-75; A higher proportion of patients reaching PASI-75 means betterment in higher proportion of patients Week 16
Other Proportion of patients achieving PASI 90 response PASI-90; A higher proportion of patients reaching PASI-90 means betterment in higher proportion of patients Week 16
Other Proportion of patients achieving PASI 100 response PASI-100; A higher proportion of patients reaching PASI-100 means betterment in higher proportion of patients Week 16
Other Proportion of patients achieving PASI 50 response PASI-50; A higher proportion of patients reaching PASI-50 means betterment in higher proportion of patients Week 16
Other Proportion of patients achieving IGA 0 or 1 response IGA 0 or 1; A higher proportion of patients reaching IGA 0 or 1 means betterment in higher proportion of patients Week 16
Other Proportion of patients achieving DLQI 0 or 1 score DLQI 0 or 1; A higher proportion of patients reaching DLQI 0 or 1 means betterment in higher proportion of patients Week 16
Other Percent change from baseline in PASI score at week 16 Percent change from baseline Week 16
Primary Proportion of patients achieving PASI 75 response (i.e. 75 percent reduction from baseline PASI [Psoriasis Area and Severity Index] score) at the end of week 12. PASI-75; A higher proportion of patients reaching PASI-75 means betterment in higher proportion of patients Week 12
Secondary Proportion of patients achieving PASI 75 response (i.e. 75 percent reduction from baseline PASI [Psoriasis Area and Severity Index] score) at the end of week 4 and 8 PASI-75; A higher proportion of patients reaching PASI-75 means betterment in higher proportion of patients Week 4 and Week 8
Secondary Proportion of patients achieving PASI 50, PASI 90 and PASI 100 response at week 12. PASI-50, PASI-90, PASI-100; A higher proportion of patients reaching PASI-50, PASI-90 or PASI-100 means betterment in higher proportion of patients Week 12
Secondary Proportion of patients achieving IGA 0 or 1 at week 12 IGA (Investigator's Global Assessment); Lower scores are better Week 12
Secondary Percent change from baseline in PASI score at week 12 Percent Change in PASI from baseline Week 12
Secondary Percent change from baseline to week 12 in percent BSA involved Percent Change in BSA (body surface area) from baseline Week 12
Secondary Proportion of patients achieving DLQI score of 0 or 1 at week 12 DLQI (Dermatology Life Quality Index) Score; Lower scores are better; Maximum score of 30 and minimum of 0 Week 12
Secondary Plasma Pharmacokinetic parameters at week 4 Cmax (maximum Plasma concentration) Week 4
Secondary Plasma Pharmacokinetic parameters at week 4 AUC0-8 (Area Under The Curve for 8 hours) after morning drug administration Week 4
Secondary Nature and incidence of Treatment Emergent Adverse Events (TEAEs) All Adverse Events which occur from the administration of study drug From Day 1 through Follow Up Visit at Week 14
Secondary Changes in Blood Pressure Both systolic and diastolic Blood Pressure changes during trial will be measured From Day 1 through Follow Up Visit at Week 14
Secondary Changes in Pulse Rate Pulse Rate changes during trial From Day 1 through Follow Up Visit at Week 14
Secondary Changes in Temperature Body temperature changes during trial From Day 1 through Follow Up Visit at Week 14
Secondary Changes in Respiratory Rate Respiratory Rate changes during trial From Day 1 through Follow Up Visit at Week 14
Secondary Changes in PR interval in ECG (Electro Cardio Gram) Changes in PR Interval Week 14 (Follow Up Visit)
Secondary Changes in QRS interval in ECG (Electro Cardio Gram) Changes in QRS Interval Week 14 (Follow Up Visit)
Secondary Changes in QTc interval in ECG (Electro Cardio Gram) Changes in QTc Interval Week 14 (Follow Up Visit)
Secondary Changes in CBC (Complete Blood Count) Complete Blood Count (CBC) From Day 1 through Follow Up Visit at Week 14
Secondary Changes in Liver Function Tests Liver Function Tests (AST, ALT, Total Bilirubin) From Day 1 through Follow Up Visit at Week 14
Secondary Changes in weight Weight (in pounds) will be measured at all visits and change in weight (in pounds) will be presented From Day 1 through Follow Up Visit at Week 14
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03638258 - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2